RxDoctor Payments DataLook up a doctor →

Mohammad Khan, DO

Pulmonary Disease · Akron, OHNPI 1760610919

Payments from drug & device makers

$388,452in general payments, 2019–2025

Across 770 payments — averaging $504.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$381K
  • Viiv Healthcare Company$2K
  • AstraZeneca$1K
  • Boehringer Ingelheim$644
  • United Therapeutics Corporation$630
  • Jazz Pharmaceuticals Inc.$350
  • plus $3K from 39 others

What the payments were for

  • Consulting fees$5,5251%
  • Speaking & faculty fees$357,97592%
  • Travel & lodging$8,6462%
  • Food & beverage$16,2524%
  • Education$370%
  • Gifts$170%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$388,452 in reported general payments places this provider in the 95th percentile of 571 pulmonary disease providers in Ohio.

See all pulmonary disease providers in Ohio

Medicare billing

Part B allowed, 2024
$80,084
Medicare patients
253
Services billed
662

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter277$317,384
NucalaMepolizumab18$73,896
Stiolto RespimatTiotropium Br/Olodaterol Hcl91$68,278
Pirfenidone17$58,048
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr70$52,798
Breztri AerosphereBudesonide/Glycopyr/Formoterol53$47,409
Spiriva RespimatTiotropium Bromide61$45,812
Breo ElliptaFluticasone/Vilanterol70$45,064
XareltoRivaroxaban37$25,316
SymbicortBudesonide/Formoterol Fumarate44$14,379
Fluticasone-SalmeterolFluticasone Propion/Salmeterol50$11,038
Albuterol Sulfate HfaAlbuterol Sulfate268$10,566
Incruse ElliptaUmeclidinium Bromide20$9,994
Combivent RespimatIpratropium/Albuterol Sulfate14$8,523
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate51$8,362

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Breo Ellipta, Incruse Ellipta$381,360$499,137455 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat, Combivent Respimat$644$122,614166 claims
AstraZenecaBreztri Aerosphere, Symbicort$1,069$61,78897 claims
Johnson & JohnsonXarelto$83$25,31637 claims
MerckDulera$103$7,82826 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 571 pulmonary disease providers in Ohio.

Other pulmonary disease in Akron

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →